Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

@article{Galsky2011TreatmentOP,
  title={Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.},
  author={Matthew D Galsky and Noah M. Hahn and Jonathan E Rosenberg and Guru P. Sonpavde and Thomas Hutson and William K. Oh and Robert Dreicer and Nicholas J Vogelzang and Cora N Sternberg and Dean F Bajorin and Joaquim Bellmunt},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 17},
  pages={
          2432-8
        }
}
  • Matthew D Galsky, Noah M. Hahn, +8 authors Joaquim Bellmunt
  • Published 2011
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • PURPOSE Cisplatin-based combination chemotherapy is considered standard first-line treatment for patients with metastatic urothelial carcinoma. However, a large proportion of patients with metastatic urothelial carcinoma are considered "unfit" for cisplatin. The purpose of this review is to define unfit patients and to identify treatment options for this subgroup of patients. PATIENTS AND METHODS In this review, the criteria used to define unfit patients are explored and the results of… CONTINUE READING

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2… Expand
    ConditionsBladder Carcinoma
    InterventionDrug
    INTERVENTIONAL CLINICAL TRIAL
    Phase II Multicentre, randomized, open-label study to evaluate the safety and efficacy of avelumab with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with… Expand
    ConditionsMetastatic Urothelial Cancer
    InterventionCombination Product

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 180 CITATIONS, ESTIMATED 29% COVERAGE

    [Urothelial cancer: update on systemic treatment options].

    VIEW 2 EXCERPTS
    CITES BACKGROUND

    Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer

    VIEW 2 EXCERPTS
    CITES RESULTS & BACKGROUND

    FILTER CITATIONS BY YEAR

    2011
    2020

    CITATION STATISTICS

    • 3 Highly Influenced Citations

    • Averaged 32 Citations per year from 2018 through 2020

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 63 REFERENCES

    Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.